SBIR and STTR Success Story for
LigoCyte Pharmaceuticals

(Information Posted/Updated on 08/10/2007)

LigoCyte Pharmaceuticals
2155 Analysis Drive
Bozeman, MT  59718-6831

Contact:    Robert F. Bargatze, Ph.D.
Phone:      406-585-2733
Fax:          406-585-2766
Web Site:

Project Title:  Rational Design of Adhesion Blocking Anti-Inflammatories
Related Award(s):  R44 A143789-04; 5RR44 AI43789-6
Technology Developed:
LigoCyte has developed a monoclonal antibody capable of inhibiting inflammatory disease in the lung.

Key Words:  chronic inflammation, antibody, adhesion, pulmonary.
Uses of Technology/Products/Service:
This technology is a therapeutic drug to treat chronic inflammatory disease.

Benefit to Company:
The SBIR program has had a profound impact on the ability of the company to develop this technology. Using data generated through research performed under the grant, LigoCyte was able to secure a pharmaceutical partner for the technology who is supporting further development, human clinical testing, manufacturing and product sales.

How Product Was Commercialized:
In continuing partner discussions.

Other Comments Related to Company's Success Story:
Human therapeutic mAb candidates generated and in preclinical development.